CL2013000360A1 - Virus varicela zoster inactivado; composicion farmaceutica que comprende una cantidad de dicho virus; metodos para preparar dicho virus; vacuna que comprende el virus; uso de la vacuna para tratar herpes zóster. - Google Patents

Virus varicela zoster inactivado; composicion farmaceutica que comprende una cantidad de dicho virus; metodos para preparar dicho virus; vacuna que comprende el virus; uso de la vacuna para tratar herpes zóster.

Info

Publication number: CL2013000360A1
Authority: CL; Chile
Prior art keywords: virus; vaccine; preparing; methods; pharmaceutical composition
Prior art date: 2010-08-05

Application number

CL2013000360A

Other languages

English (en)

Inventor

David L Krah

Jill Dehaven

Jennifer A Kriss

Colleen M Barr

Mary Yagodich

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-08-05

Filing date

2013-02-05

Publication date

2014-03-28

2013-02-05 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2014-03-28 Publication of CL2013000360A1 publication Critical patent/CL2013000360A1/es

Links

241000700605 Viruses Species 0.000 title 3
229960005486 vaccine Drugs 0.000 title 2
208000007514 Herpes zoster Diseases 0.000 title 1
241000701085 Human alphaherpesvirus 3 Species 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Mycology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CL2013000360A 2010-08-05 2013-02-05 Virus varicela zoster inactivado; composicion farmaceutica que comprende una cantidad de dicho virus; metodos para preparar dicho virus; vacuna que comprende el virus; uso de la vacuna para tratar herpes zóster. CL2013000360A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37103810P	2010-08-05	2010-08-05

Publications (1)

Publication Number	Publication Date
CL2013000360A1 true CL2013000360A1 (es)	2014-03-28

Family

ID=45556327

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2013000360A CL2013000360A1 (es)	2010-08-05	2013-02-05	Virus varicela zoster inactivado; composicion farmaceutica que comprende una cantidad de dicho virus; metodos para preparar dicho virus; vacuna que comprende el virus; uso de la vacuna para tratar herpes zóster.
CL2016003181A CL2016003181A1 (es)	2010-08-05	2016-12-12	Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas (divisional de sol. n° 360-13).

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CL2016003181A CL2016003181A1 (es)	2010-08-05	2016-12-12	Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas (divisional de sol. n° 360-13).

Country Status (23)

Country	Link
US (3)	US20120034267A1 (es)
EP (2)	EP3363894A1 (es)
JP (2)	JP2013535488A (es)
KR (3)	KR20160060790A (es)
CN (1)	CN103167880B (es)
AR (1)	AR082577A1 (es)
AU (1)	AU2011285749B2 (es)
BR (1)	BR112013001946A2 (es)
CA (1)	CA2806454A1 (es)
CL (2)	CL2013000360A1 (es)
CO (1)	CO6731067A2 (es)
EC (1)	ECSP13012476A (es)
MX (1)	MX343600B (es)
MY (1)	MY158419A (es)
NZ (1)	NZ606549A (es)
PE (1)	PE20131336A1 (es)
PH (1)	PH12013500133A1 (es)
RU (1)	RU2633058C2 (es)
SG (1)	SG187222A1 (es)
TW (1)	TW201208698A (es)
UA (1)	UA112970C2 (es)
WO (1)	WO2012018973A1 (es)
ZA (1)	ZA201300622B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3041505A4 (en)	2013-09-05	2017-04-19	Merck Sharp & Dohme Corp.	Methods of immunization with varicella zoster virus antigen
RU2651040C2 (ru) *	2016-08-08	2018-04-18	Федеральное государственное бюджетное учреждение "48 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации	Вакцина оспенная инактивированная эмбриональная сухая таблетированная для орального применения "ТЭОВин" и способ ее получения
RU2637093C1 (ru) *	2016-12-20	2017-11-29	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова)	Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы
CN107174658B (zh) *	2017-04-29	2020-11-27	安徽智飞龙科马生物制药有限公司	人用水痘病毒灭活疫苗及其制备方法
CN109453371A (zh) *	2018-11-23	2019-03-12	中国兽医药品监察所	一种羊痘、山羊传染性胸膜肺炎二联灭活疫苗及其生产方法
RU2700410C1 (ru) *	2019-05-20	2019-09-17	Федеральное государственное бюджетное учреждение науки "Национальный научный центр морской биологии им. А.В. Жирмунского" Дальневосточного отделения Российской академии наук (ННЦМБ ДВО РАН)	Метод иммуноокрашивания биологического материала для конфокальной микроскопии
EP4076515A1 (en)	2019-12-16	2022-10-26	Intervet International B.V.	Inactivated piscine orthoreovirus vaccine
WO2024191324A1 (ru) *	2023-03-13	2024-09-19	Олег Александрович ШИЛОВ	Способ получения препарата вакцины из цельных вирусов или бактерий

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5341202B2 (es)	1974-03-12	1978-11-01
DE2714665A1 (de) *	1977-04-01	1978-10-05	Mayr Anton	Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
AU687355B2 (en) *	1992-07-17	1998-02-26	Merck Sharp & Dohme Corp.	Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
US6022876A (en) *	1996-11-15	2000-02-08	Yale University	L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
GB9921146D0 (en) *	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
EP1286706A2 (en) *	2000-05-17	2003-03-05	The American National Red Cross	Gamma irradiation of protein-based pharmaceutical products
US6946098B2 (en) *	2001-08-10	2005-09-20	Clearant, Inc.	Methods for sterilizing biological materials
US20050175630A1 (en) *	2003-12-23	2005-08-11	Eyal Raz	Immunogenic compositions and methods of use thereof
CA2558586A1 (en) *	2004-03-05	2005-09-15	The Research Foundation For Microbial Diseases Of Osaka University	Recombinant varicella-zoster virus
GB0504436D0 (en) *	2005-03-03	2005-04-06	Glaxosmithkline Biolog Sa	Vaccine
MY172788A (en) *	2008-08-01	2019-12-12	Gamma Vaccines Pty Ltd	Influenza vaccines

2011
- 2011-04-08 UA UAA201302742A patent/UA112970C2/uk unknown
- 2011-08-04 NZ NZ606549A patent/NZ606549A/en not_active IP Right Cessation
- 2011-08-04 CA CA2806454A patent/CA2806454A1/en not_active Abandoned
- 2011-08-04 EP EP18160689.8A patent/EP3363894A1/en not_active Withdrawn
- 2011-08-04 JP JP2013523327A patent/JP2013535488A/ja active Pending
- 2011-08-04 PH PH1/2013/500133A patent/PH12013500133A1/en unknown
- 2011-08-04 US US13/198,191 patent/US20120034267A1/en not_active Abandoned
- 2011-08-04 KR KR1020167013241A patent/KR20160060790A/ko not_active Ceased
- 2011-08-04 WO PCT/US2011/046534 patent/WO2012018973A1/en not_active Ceased
- 2011-08-04 BR BR112013001946A patent/BR112013001946A2/pt not_active IP Right Cessation
- 2011-08-04 TW TW100127807A patent/TW201208698A/zh unknown
- 2011-08-04 EP EP11815299.0A patent/EP2600893A4/en not_active Ceased
- 2011-08-04 CN CN201180046512.6A patent/CN103167880B/zh not_active Expired - Fee Related
- 2011-08-04 MY MYPI2013000290A patent/MY158419A/en unknown
- 2011-08-04 KR KR1020167002433A patent/KR20160018828A/ko not_active Ceased
- 2011-08-04 RU RU2013109417A patent/RU2633058C2/ru not_active IP Right Cessation
- 2011-08-04 SG SG2013006515A patent/SG187222A1/en unknown
- 2011-08-04 MX MX2013001434A patent/MX343600B/es active IP Right Grant
- 2011-08-04 KR KR1020137002903A patent/KR20130036062A/ko not_active Ceased
- 2011-08-04 AU AU2011285749A patent/AU2011285749B2/en not_active Ceased
- 2011-08-04 PE PE2013000202A patent/PE20131336A1/es not_active Application Discontinuation
- 2011-08-05 AR ARP110102849A patent/AR082577A1/es unknown
2013
- 2013-01-23 ZA ZA2013/00622A patent/ZA201300622B/en unknown
- 2013-02-01 CO CO13019546A patent/CO6731067A2/es unknown
- 2013-02-05 CL CL2013000360A patent/CL2013000360A1/es unknown
- 2013-03-04 EC ECSP13012476 patent/ECSP13012476A/es unknown
2015
- 2015-04-03 US US14/678,542 patent/US20150209424A1/en not_active Abandoned
- 2015-10-02 JP JP2015196551A patent/JP2016053032A/ja active Pending
2016
- 2016-12-12 CL CL2016003181A patent/CL2016003181A1/es unknown
2018
- 2018-07-03 US US16/026,779 patent/US20180318412A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2600893A1 (en)	2013-06-12
PH12013500133A1 (en)	2013-03-11
AU2011285749B2 (en)	2014-07-31
US20150209424A1 (en)	2015-07-30
EP2600893A4 (en)	2014-01-22
NZ606549A (en)	2014-12-24
SG187222A1 (en)	2013-03-28
MX2013001434A (es)	2013-03-12
KR20130036062A (ko)	2013-04-09
CA2806454A1 (en)	2012-02-09
RU2633058C2 (ru)	2017-10-11
ECSP13012476A (es)	2013-04-30
UA112970C2 (uk)	2016-11-25
TW201208698A (en)	2012-03-01
PE20131336A1 (es)	2013-11-21
KR20160018828A (ko)	2016-02-17
CN103167880B (zh)	2016-05-18
EP3363894A1 (en)	2018-08-22
AR082577A1 (es)	2012-12-19
ZA201300622B (en)	2013-09-25
WO2012018973A1 (en)	2012-02-09
CL2016003181A1 (es)	2017-06-02
JP2013535488A (ja)	2013-09-12
RU2013109417A (ru)	2014-09-10
BR112013001946A2 (pt)	2016-05-24
US20120034267A1 (en)	2012-02-09
US20180318412A1 (en)	2018-11-08
MX343600B (es)	2016-11-10
CO6731067A2 (es)	2013-08-15
KR20160060790A (ko)	2016-05-30
CN103167880A (zh)	2013-06-19
MY158419A (en)	2016-10-14
AU2011285749A1 (en)	2013-01-31
JP2016053032A (ja)	2016-04-14

Publication	Publication Date	Title
CL2013000360A1 (es)	2014-03-28	Virus varicela zoster inactivado; composicion farmaceutica que comprende una cantidad de dicho virus; metodos para preparar dicho virus; vacuna que comprende el virus; uso de la vacuna para tratar herpes zóster.
ECSP21072161A (es)	2021-11-18	Composiciones de liberación retardada de linaclotida
CR20140034A (es)	2014-07-23	Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
BR112013011949A2 (pt)	2016-08-23	"indóis, composição farmacêutica que os compreende, seus processos de preparação e uso dos ditos indóis"
BR112013020070A2 (pt)	2018-03-06	moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
CL2012002489A1 (es)	2012-11-30	Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
BR112014001255A2 (pt)	2017-02-21	composto, uso de um composto, combinação, e, composição farmacêutica
CL2014001641A1 (es)	2014-12-12	Compuestos derivados de nucleosidos sustituidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y uso para mejorar o tratar una infeccion viral.
BR112014013760A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
BR112013023174A2 (pt)	2016-08-09	"compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos"
HRP20182194T1 (hr)	2019-02-22	Onkolitički herpes simpleks virus i njegova terapeutska uporaba
PT2898885T (pt)	2018-02-05	Derivados de pirrolopirimidina para utilização no tratamento de infeções virais
BR112013015816A2 (pt)	2018-05-29	construção de dna para imunomodulação, composição farmacêutica, vacina e uso de uma construção de dna
CL2013002123A1 (es)	2014-04-04	Composicion herbicida que comprende topramezona y pinoxaden; uso de dicha composicion para controlar vegetación indeseable; formulación indeseable.
BR112014001049A2 (pt)	2017-02-21	método para a produção de um antígeno viral derivado de vírus envelopado, e, uso de um método para a fabricação de uma preparação de vacina contendo o antígeno viral
EP2595653A4 (en)	2014-03-12	INFLUENZA VACCINE
BR112014005406A2 (pt)	2017-03-28	composição de vacina e respectivo uso
NI201200157A (es)	2013-02-05	Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CL2014002986A1 (es)	2015-01-09	Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
BR112014013178A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
CL2013001129A1 (es)	2014-03-21	Composicion que comprende una celula madre gbm6-ad de glioblastoma purificada; metodo de generacion de anticuerpos especificos para gbm6-ad; dicho anticuerpo; metodo para producir una vacuna de celulas dendriticas; y su uso para el tratamiento de cancer.
EP2516629A4 (en)	2013-09-04	VACCINES AGAINST HERPES SIMPLEX VIRUS
BR112014013177A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
BR112014026564A2 (pt)	2017-06-27	formulação, uso de uma formulação, e, processo para a preparação de uma formulação
BR112013015083A2 (pt)	2016-08-09	sistema para uso com um poço